News | Radiation Therapy | September 21, 2017

Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017

CyberKnife System with Accuray Precision TPS leads new technology highlights

Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017

September 21, 2017 — Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be shared by leading radiation oncology practitioners at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 24-27 in San Diego.

Technology highlights from the show will include:

  • The CyberKnife System upgrade with the Accuray Precision Treatment Planning System (TPS): the fully integrated Accuray TPS allows clinicians to reduce treatment times, while advanced TPS features enhance workflow efficiencies;
  • The Radixact System: the next-generation TomoTherapy platform represents a major step forward in treatment speed, efficiency and ease of use, enabling customers to deliver precise radiation treatments to a high volume of patients; and
  • The CyberKnife System High-Definition ImagingRing (HDI): a cone beam computed tomography (CBCT) imaging system designed to enable both 3-D volumetric imaging and adaptive radiotherapy workflows. When paired with the system's accurate couch imaging and patient registration, along with true robotic alignment, it is projected to facilitate high precision and versatility in stereotactic radiosurgery and stereotactic body radiation therapy. The CyberKnife System HDI is a work in progress and not available for sale in any market.

ASTRO attendees can attend educational symposia and Accuray Exchange in Radiation Oncology (AERO) Academy sessions to learn about advances in clinical practice that are transforming patient experience and outcomes.

 

For more information: www.accuray.com

Related Content

Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at th
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...